New York CNN —America’s gyms are adjusting their strategies as more of their members take weight loss drugs. JPMorgan researchers estimate that 30 million people may be taking GLP-1 drugs by 2030, or around 9% of the US population. For now, GLP-1 medications are prohibitively expensive for most Americans, costing about $1,000 or more a month. (Ozempic has not been approved for weight loss by regulators, though Wegovy, a similar drug, has.) It also made a $100 million-plus deal to buy Sequence, a telehealth business that offers virtual prescriptions to patients for these weight loss drugs where appropriate.

---

Persons: ”, Simeon Siegel, Bahram Akradi, “, Amanda Edwards, ” Siegel, Rick Caro, Jaap Arriens, WeightWatchers Organizations: New, New York CNN, Boomers, JPMorgan, Fitness, BMO Capital Markets, Management, Industries Locations: New York, Ozempic, Barre, Southern California